Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio ...

Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a proprietary high-concentration subcutaneous co-formulation consisting of HER2 ...

This article was reviewed by Lynn Marie Morski, MD, JD. Key Takeaways: You can take Mounjaro at any time of day. The best ...

Tirzepatide is noninferior to dulaglutide with respect to a composite of death from cardiovascular (CV) causes, myocardial ...

On Monday evening, the Food and Drug Administration approved Novo Nordisk’s high-dose oral formulation of semaglutide for ...

As of Wednesday, December 31, Xeris Biopharma Holdings, Inc.’s XERS share price has surged by 8.66%, which has investors questioning if this is right time to sell.

VKTX remains a Buy for its cheap FY2030 EV/Sales valuations of 2.28x, the strong clinical trial results exceeding legacy ...

Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma (TM), a ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous formulation for the treatment of adult patients ...

Samsung Bioepis Co. Ltd. has announced the marketing approval of Ustekinumab BS Subcutaneous Injection 45mg Syringes 'NIPRO', ...

The MHRA has approved depemokimab as an add-on treatment for severe asthma and chronic rhinosinusitis with nasal polyps.

Novo Nordisk should remain one of the leaders in the fast-growing weight loss market, and the company's shares are trading at ...